TABLE 3.
Treatment Differences in Time Periods by Medication Type, 2000-2009, Percentage of Constipation and/or IBS Visits with Prescribed Medication (Range)
Age Range, Years | Weighted Number of Visits (Millions) | Time Period | Lubiprostone | Stimulant Laxative | Stool Softener | Prokinetic | Lubricant | Hyperosmolar Agent | Saline Laxative | Sodium Phosphate | Tegaserod | Fiber, Any | Combination Therapya |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
< 18 | 1.2 | 2000-2004 | — | 10 (4-23) | 6 (2-15) | 2 (1-8) | 17 (9-32)b | 74 (58-85)c | 6 (2-17)b | — | — | 3 (1-13) | 17 (8-31) |
2005-2009 | — | 8 (4-17) | 3 (1-8) | — | 2 (0-7)b | 90 (82-95)c | 0 (0-1)b | — | — | 3 (1-9) | 6 (2-14) | ||
18-44 | 9.4 | 2000-2004 | — | 3 (1-11)c | 21 (9-42) | 4 (1-24) | 2 (0-8) | 34 (19-53) | 3 (1-12) | 0 (0-2) | 22 (9-42) | 25 (14-40) | 15 (5-38) |
2005-2009 | 9 (3-21) | 15 (7-28)c | 13 (6-27) | 6 (1-23) | 4 (1-23) | 36 (23-51) | 0 (0-2) | — | 8 (2-30) | 24 (12-41) | 19 (10-33) | ||
45-64 | 10.5 | 2000-2004 | — | 13 (4-32)c | 9 (3-24) | 9 (3-24) | — | 44 (30-60) | 6 (1-19) | — | 11 (4-28) | 14 (6-30) | 4 (1-19) |
2005-2009 | 6 (2-17) | 1 (0-5)c | 8 (3-16) | 3 (1-14) | — | 55 (39-69) | 1 (0-4) | — | 13 (6-26) | 15 (7-29) | 4 (1-10) | ||
≥ 65 | 2.8 | 2000-2004 | — | 9 (3-20) | 20 (10-37) | 2 (1-8) | 3 (1-12) | 39 (24-56) | 10 (4-22)c | 3 (1-13) | 14 (5-30)c | 23 (13-38) | 23 (12-37) |
2005-2009 | 6 (2-15) | 8 (4-16) | 21 (12-33) | 4 (1-15) | 0 (0-2) | 46 (34-58) | 2 (0-7)c | — | 2 (1-8)c | 29 (19-43) | 18 (10-29) | ||
All visits | 28.2 | 2000-2004 | — | 8 (5-14) | 13 (8-21) | 3 (1-9) | 8 (4-13)b | 52 (42-61) | 6 (3-11)b | 1 (0-3) | 10 (6-17) | 15 (10-21) | 16 (10-24) |
2005-2009 | 5 (3-9) | 8 (5-12) | 11 (8-16) | 3 (1-8) | 2 (0-5)b | 58 (50-65) | 1 (0-2)b | — | 5 (3-10) | 18 (13-25) | 12 (8-17) |
Note: empty cells indicate zero occurances in the sample
aRepresents patients prescribed at least 1 medication and nonpharmacologic treatment.
bP < 0.01.
cP < 0.05 for 2000-2004 versus 2005-2009.
IBS = irritable bowel syndrome.